

February 26, 2018
CYBERDYNE, INC.
CureApp, Inc.

CYBERDYNE and CureApp form a business and capital alliance
~ combining Cybernic Technology and treatment application to promote
personalized medicine with mobile devices ~

CYBERDYNE, INC. [Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai (“Cyberdyne”)] and CureApp, Inc. [Chuo-ku, Tokyo, CEO: Kota Satake (“CureApp”)] announced that they formed a capital tie-up (Cyberdyne’s investment in CureApp) and a business alliance towards promotion of advanced personalized medicine with mobile devices. Cyberdyne will support the business of CureApp and also combine its Cybernic Technology with treatment applications of CureApp. Through these endeavor, the two companies aim to promote advanced personalized medicine with mobile devices by utilizing medical Big Data that are obtained through various Cybernic Devices linked in Internet of Humans/Internet of Things (“IoH/IoT”).

CureApp is a venture company that was founded in July 2014 by medical doctors to develop medical devices with “Treatment Application” based on medical evidence. Treatment Application developed by CureApp allows a doctor to provide off-site, and real-time treatment-intervention in various aspects of a patient’s daily life including its awareness, habits and time schedule. The appropriately can follow it up according to the patient’s personal conditions. To realize the first medical service with “the clinically effective application on improvement of diseases” in Japan, CureApp develops applications for mobile devices, such as “CureApp Smoking Cessation” for treatment of nicotine addiction and “CureApp NASH” for treatment of non-alcoholic steatohepatitis, “NASH”. Clinical trials and clinical researches are currently in progress to evaluate the clinical effects of the aforementioned applications.

In the field of medicine, Cyberdyne develops innovative products such as HAL for Medical Use Lower Limb Type that is designed to improve and regenerate the motor



function of its wearer. It also develops Vital Sensor that is designed for daily monitoring of arterial hardening and cardiac arrhythmias to prevent lifestyle-related diseases. Furthermore, as one of the center partners of World Economic Forum 4th Industrial Revolution Center, Cyberdyne is currently working on the Precision Medicine Project to promote various forms of personalized medicine. In order to improve the condition of a patient in a true sense, it is necessary to improve the awareness, action and habit of the patient by making intervention in their lives outside of the hospital. With an aim to promote this advanced personalized IoH/IoT medicine, the two companies entered into this business and capital alliance. Through this alliance, Cyberdyne and CureApp will fully utilize the cutting-edge technology to overcome the increase in medical cost that is caused by the trend of aging and improving longevity. The two companies aim to contribute to the realization of the society of good health and longevity where everyone could live long, comfortably and healthily, while challenging to solve social problems such as impending situation of health financing and burdening care.

<About Cyberdyne>

Since its establishment as a venture company from the University of Tsukuba in 2004, Cyberdyne has promoted the comprehensive development of various Cybernic Systems (Cybernic devices, Cybernic interfaces, etc.) that utilize Cybernic Technology from research and development to social implementation, aiming to tackle the various issues facing society. The company has developed business in the fields of medicine, welfare and daily living (including the work environment), and its main product, Robot Suit HAL®, is widely distributed not only in the medical and welfare fields but also in care support and labor support fields. In addition, new products such as Transportation Robot and Cleaning Robot equipped with artificial intelligence and environment recognition functions, HAL Lumbar Type for reduction of the load and stress on the lower back, smaller-sized HAL (Single-Joint Type), Vital Sensor for arteriosclerosis and arrhythmia measurements are continuously developed. For more details, please refer to the following website: www.cyberdyne.jp/eng/.



<About CureApp>

CureApp, Inc. is a MedTech venture company that researches, develops and manufactures Medical devices and software with “Treatment Application” based on medical evidence. To realize the first medical service of “clinically effective application on improvement of diseases” in Japan, CureApp develops a “Treatment Application” for mobile devices. Based on the information input by the patient, the “Treatment Application” will analyze and provide sufficient guidance that is backed-up with medical knowledge and evidence. As the application might influence the patient’s awareness, action and daily habits, it is probable that the conditions of the patient would improve. CureApp, Inc. became the first Japanese company to start the clinical trial for Treatment Application, which is currently in progress. CureApp, Inc. is also working on Treatment Application for other diseases in order to become the global digital health solution provider that is originated in Japan.